HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements.

Abstract
Immunotherapies for various neurodegenerative diseases have recently emerged as a promising approach for clearing pathological protein conformers in these disorders. This type of treatment has not been assessed in models that develop neuronal tau aggregates as observed in frontotemporal dementia and Alzheimer's disease. Here, we present that active immunization with a phosphorylated tau epitope, in P301L tangle model mice, reduces aggregated tau in the brain and slows progression of the tangle-related behavioral phenotype. Females had more tau pathology than males but were also more receptive to the immunotherapy. The tau antibodies generated in these animals recognized pathological tau on brain sections. Performance on behavioral assays that require extensive motor coordination correlated with tau pathology in corresponding brain areas, and antibody levels against the immunogen correlated inversely with tau pathology. Interestingly, age-dependent autoantibodies that recognized recombinant tau protein but not the immunogen were detected in the P301L mice. To confirm that anti-tau antibodies could enter the brain and bind to pathological tau, FITC-tagged antibodies purified from a P301L mouse, with a high antibody titer against the immunogen, were injected into the carotid artery of P301L mice. These antibodies were subsequently detected within the brain and colocalized with PHF1 and MC1 antibodies that recognize pathological tau. Currently, no treatment is available for clearing tau aggregates. Our present findings may lead to a novel therapy targeting one of the major hallmarks of Alzheimer's disease and frontotemporal dementia.
AuthorsAyodeji A Asuni, Allal Boutajangout, David Quartermain, Einar M Sigurdsson
JournalThe Journal of neuroscience : the official journal of the Society for Neuroscience (J Neurosci) Vol. 27 Issue 34 Pg. 9115-29 (Aug 22 2007) ISSN: 1529-2401 [Electronic] United States
PMID17715348 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Antibodies
  • tau Proteins
  • Proline
  • Leucine
Topics
  • Age Factors
  • Analysis of Variance
  • Animals
  • Antibodies (therapeutic use)
  • Behavior, Animal
  • Brain (drug effects, metabolism, pathology)
  • Cell Line, Tumor
  • Dementia (genetics, pathology, therapy)
  • Disease Models, Animal
  • Humans
  • Immunotherapy (methods)
  • Leucine (genetics)
  • Mice
  • Mice, Transgenic
  • Motor Activity (drug effects, physiology)
  • Neuroblastoma
  • Proline (genetics)
  • Psychomotor Performance (drug effects, physiology)
  • Recognition, Psychology (drug effects, physiology)
  • Sex Factors
  • tau Proteins (genetics, immunology, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: